P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia

Kevin Lin(The University of Texas MD Anderson Cancer Center), Kris C. Wood(Duke University), Paul-Arthur Meslin(Centre National de la Recherche Scientifique), Antoine Forget(Centre National de la Recherche Scientifique), Ashutosh Chilkoti(Duke University), Shane T. Killarney(Duke University), Gaetano Sodaro(Centre National de la Recherche Scientifique), Kouros Owzar(Duke University), Christian Cerda-Smith(Duke University), Min Lu(Vanderbilt University), Arnaud Jacquel(Inserm), Abigail Xie(Duke University), Alexandre Puissant(Délégation Paris 5), Patrick Auberger(Inserm), Camille Vaganay(Inserm), Lina Benajiba(Inserm), Timothy S. Pardee(Atrium Health Wake Forest Baptist), Jiaxing Lin(Duke University), Zhecheng Sheng(Duke University), Frank Ling(Centre National de la Recherche Scientifique), Rachel Washart(Duke University), Christopher F. Bassil(Duke University), Chaı̈ma Benaksas(Centre National de la Recherche Scientifique), Nina Fenouille(Délégation Paris 5), David A. Rizzieri(Duke University), Mariaelena Pierobon(George Mason University), Hazel X. Ang(Duke University), Jacob P. Hoj(Duke University), Justine C. Rutter(Duke University), Xinghai Li(Duke University), Paul Chaintreuil(Université Côte d'Azur), Emanuel F. Petricoin(Center for Biologics Evaluation and Research), Raphaël Itzykson(Université Paris-Sud)
Nature Cancer
June 6, 2022
Cited by 42


Related Papers